APO RESEARCH · REPORT
Malignant Mesothelioma Therapeutic
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Product & engineering
Understand the product.
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
Selected research
Industry Growth & Trends
Global Malignant Mesothelioma Therapeutic Industry Growth and Trends Forecast to 2032
Market perspective
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
According to APO Research, the global Malignant Mesothelioma Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Read the full market overview
Report Scope
This report provides a structured, data-driven view of the global Malignant Mesothelioma Therapeutic market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Malignant Mesothelioma Therapeutic market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Malignant Mesothelioma Therapeutic market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Malignant Mesothelioma Therapeutic.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Malignant Mesothelioma Therapeutic market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Malignant Mesothelioma Therapeutic Market by Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Malignant Mesothelioma Therapeutic Segment by Type
Pemetrexed
Cisplatin
Others
Malignant Mesothelioma Therapeutic Segment by Application
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
Malignant Mesothelioma Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Malignant Mesothelioma Therapeutic companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Pemetrexed
- Cisplatin
- Others
Applications
- Pleural Mesothelioma
- Peritoneal Mesothelioma
- Others
Companies covered
- Eli Lilly
- Teva
- Sanofi
- Bristol-Myers Squibb
- Pfizer
- Roche
- Merck
- Ono Pharmaceutical
- Mylan
- Fresenius Kabi
- Sun Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Malignant Mesothelioma Therapeutic Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Malignant Mesothelioma Therapeutic Market Size by Region (2021-2032)
- 1.4.1 Global Malignant Mesothelioma Therapeutic Market Size by Region (2021-2026)
- 1.4.2 Global Malignant Mesothelioma Therapeutic Market Size by Region (2027-2032)
- 1.5 Key Regions Malignant Mesothelioma Therapeutic Market Size (2021-2032)
- 1.5.1 North America Malignant Mesothelioma Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Malignant Mesothelioma Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.4 South America Malignant Mesothelioma Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size Growth Rate (2021-2032)
2 Malignant Mesothelioma Therapeutic Market by Type
- 2.1 Type Introduction
- 2.1.1 Pemetrexed
- 2.1.2 Cisplatin
- 2.1.3 Others
- 2.2 Global Malignant Mesothelioma Therapeutic Market Size by Type
- 2.2.1 Global Malignant Mesothelioma Therapeutic Market Size Overview by Type (2021-2032)
- 2.2.2 Global Malignant Mesothelioma Therapeutic Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Malignant Mesothelioma Therapeutic Market Size Forecasted by Type (2027-2032)
- 2.3 Global Malignant Mesothelioma Therapeutic Market Size by Regions
- 2.3.1 North America Malignant Mesothelioma Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Malignant Mesothelioma Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Malignant Mesothelioma Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Malignant Mesothelioma Therapeutic Market Size Breakdown by Type (2021-2026)
3 Malignant Mesothelioma Therapeutic Market by Application
- 3.1 Type Introduction
- 3.1.1 Pleural Mesothelioma
- 3.1.2 Peritoneal Mesothelioma
- 3.1.3 Others
- 3.2 Global Malignant Mesothelioma Therapeutic Market Size by Application
- 3.2.1 Global Malignant Mesothelioma Therapeutic Market Size Overview by Application (2021-2032)
- 3.2.2 Global Malignant Mesothelioma Therapeutic Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Malignant Mesothelioma Therapeutic Market Size Forecasted by Application (2027-2032)
- 3.3 Global Malignant Mesothelioma Therapeutic Market Size by Regions
- 3.3.1 North America Malignant Mesothelioma Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Malignant Mesothelioma Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Malignant Mesothelioma Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Malignant Mesothelioma Therapeutic Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Malignant Mesothelioma Therapeutic Industry Trends
- 4.2 Malignant Mesothelioma Therapeutic Industry Drivers
- 4.3 Malignant Mesothelioma Therapeutic Industry Opportunities and Challenges
- 4.4 Malignant Mesothelioma Therapeutic Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Malignant Mesothelioma Therapeutic Revenue (2021-2026)
- 5.2 Global Malignant Mesothelioma Therapeutic Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Malignant Mesothelioma Therapeutic Key Company Headquarters & Area Served
- 5.4 Global Malignant Mesothelioma Therapeutic Company, Product Type & Application
- 5.5 Global Malignant Mesothelioma Therapeutic Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Malignant Mesothelioma Therapeutic Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Malignant Mesothelioma Therapeutic Players Market Share by Revenue in 2025
- 5.6.3 2025 Malignant Mesothelioma Therapeutic Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Eli Lilly
- 6.1.1 Eli Lilly Company Information
- 6.1.2 Eli Lilly Business Overview
- 6.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Eli Lilly Malignant Mesothelioma Therapeutic Product Portfolio
- 6.1.5 Eli Lilly Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Teva Malignant Mesothelioma Therapeutic Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sanofi Malignant Mesothelioma Therapeutic Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer Malignant Mesothelioma Therapeutic Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Roche
- 6.6.1 Roche Company Information
- 6.6.2 Roche Business Overview
- 6.6.3 Roche Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Roche Malignant Mesothelioma Therapeutic Product Portfolio
- 6.6.5 Roche Recent Developments
- 6.7 Merck
- 6.7.1 Merck Company Information
- 6.7.2 Merck Business Overview
- 6.7.3 Merck Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Merck Malignant Mesothelioma Therapeutic Product Portfolio
- 6.7.5 Merck Recent Developments
- 6.8 Ono Pharmaceutical
- 6.8.1 Ono Pharmaceutical Company Information
- 6.8.2 Ono Pharmaceutical Business Overview
- 6.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product Portfolio
- 6.8.5 Ono Pharmaceutical Recent Developments
- 6.9 Mylan
- 6.9.1 Mylan Company Information
- 6.9.2 Mylan Business Overview
- 6.9.3 Mylan Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Mylan Malignant Mesothelioma Therapeutic Product Portfolio
- 6.9.5 Mylan Recent Developments
- 6.10 Fresenius Kabi
- 6.10.1 Fresenius Kabi Company Information
- 6.10.2 Fresenius Kabi Business Overview
- 6.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Fresenius Kabi Malignant Mesothelioma Therapeutic Product Portfolio
- 6.10.5 Fresenius Kabi Recent Developments
- 6.11 Sun Pharmaceuticals
- 6.11.1 Sun Pharmaceuticals Company Information
- 6.11.2 Sun Pharmaceuticals Business Overview
- 6.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Portfolio
- 6.11.5 Sun Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Malignant Mesothelioma Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 7.3 North America Malignant Mesothelioma Therapeutic Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Malignant Mesothelioma Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 8.3 Europe Malignant Mesothelioma Therapeutic Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Malignant Mesothelioma Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 10.3 South America Malignant Mesothelioma Therapeutic Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst